Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Clinicogenetic Risk Models in Patients Randomized to Receive Consolidative Autologous Stem-Cell Transplantation after Frontline R-CHOP for Advanced Follicular Lymphoma: An Analysis from the GLSG2000 Trial

Blood (2018) 132 (Supplement 1): 4096.

https://doi.org/10.1182/blood-2018-99-118000

Published: 2018

Journal Articles

Chemotherapy-Free Combination of Obinutuzumab and Ibrutinib in First LINE Treatment of Follicular Lymphoma. the Alternative Study By the German Low Grade Lymphoma Study Group (GLSG)

Christian Schmidt, MD, Anna-Katharina Zoellner, Vindi Jurinovic, Martin Sökler, MD, Roswitha Forstpointner, Sascha Haubner, MD, Christian Buske, MD, Andreas Viardot, MD, Ulrich Keller, Christiane Pott, Ullrich Graeven, MD, Reinhard Marks, Mathias Hänel, MD, Ruediger Liersch, Jan Dürig, Eva Hoster, Michael Unterhalt, Wolfgang Hiddemann

Blood (2018) 132 (Supplement 1): 448.

https://doi.org/10.1182/blood-2018-99-111692

Published: 2018

Journal Articles

Rituximab Maintenance after First-Line Immunochemotherapy in Mantle Cell Lymphoma: Long-Term Follow-up of the Randomized European MCL Elderly Trial

Blood (2017) 130 (Supplement 1): 153.

https://doi.org/10.1182/blood.V130.Suppl_1.153.153

Published: 2017

Journal Articles

The Addition of Rituximab to CHOP Improves Failure-Free and Overall Survival of Mantle-Cell Lymphoma Patients – a Pooled Trials Analysis of the German Low-Grade Lymphoma Study Group (GLSG)

Eva Hoster, PhD, Michael Unterhalt, MD, Michael Pfreundschuh, Michael Hallek, MD, Roswitha Forstpointner, Bernd Metzner, Hermann Einsele, Jürgen Krauter, MD, Ulrich Dührsen, Wolf-Dieter Ludwig, Josef Birkmann, Norma Peter, Wolfram Klapper, MD, Martin H. Dreyling, Wolfgang Hiddemann, MD PhD

Blood (2014) 124 (21): 1752.

https://doi.org/10.1182/blood.V124.21.1752.1752

Published: 2014

Journal Articles

Radioimmunotherapy In Relapsed/Refractory Mantle Cell Lymphoma Patients: Final Results Of a European MCL Network Phase II Trial

Simone Ferrero, Alessandro Pastore, Roswitha Forstpointner, M.D., Christian W. Scholz, Antonio Pezzutto, Lothar Bergmann, Lorenz Truemper, Juergen Finke, Ulrich Keller, Marco Ladetto, Wolfgang Hiddemann, M.D., Oliver Weigert, Michael Unterhalt, Martin Dreyling

Blood (2013) 122 (21): 4384.

https://doi.org/10.1182/blood.V122.21.4384.4384

Published: 2013

Journal Articles

Evaluation Of Myeloablative Therapy Followed By Autologous Stem Cell Transplantation In First Remission In Patients With Advanced Stage Follicular Lymphoma After Initial Immuno-Chemotherapy (R-CHOP) Or Chemotherapy Alone: Analysis Of 940 Patients Treated In Prospective Randomized Trials Of The German Low Grade Lymphoma Study Group (GLSG)

Wolfgang Hiddemann, M.D., Martin H. Dreyling, M.D. Ph.D., Bernd Metzner, M.D., Michael Pfreundschuh, M.D. Ph.D., Martin Wilhelm, M.D. Ph.D., Eva Lengfelder, M.D. Ph.D., Georg Hess, M.D. Ph.D., Michael Hallek, M.D. Ph.D., Norbert Schmitz, M.D. Ph.D., Christiane Pott, M.D. Ph.D., Thomas Fischer, M.D. Ph.D., Roswitha Forstpointner, M.D., Eva Hoster, Ph.D., Michael Unterhalt, M.D. Ph.D.

Blood (2013) 122 (21): 419.

https://doi.org/10.1182/blood.V122.21.419.419

Published: 2013

Journal Articles

Alternating Courses of 3x CHOP and 3x DHAP Plus Rituximab Followed by a High Dose ARA-C Containing Myeloablative Regimen and Autologous Stem Cell Transplantation (ASCT) Is Superior to 6 Courses CHOP Plus Rituximab Followed by Myeloablative Radiochemotherapy and ASCT In Mantle Cell Lymphoma: Results of the MCL Younger Trial of the European Mantle Cell Lymphoma Network ( MCL net )

Blood (2010) 116 (21): 110.

https://doi.org/10.1182/blood.V116.21.110.110

Published: 2010

Journal Articles

Autologous Stem Cell Transplantation and Addition of Rituximab Independently Prolong Response Duration in Advanced Stage Mantle Cell Lymphoma.

Eva Hoster, Bernd Metzner, Roswitha Forstpointner, Michael Pfreundschuh, Lorenz Trümper, Michael Hallek, Bernhard Wörmann, Ulrich Dührsen, MD, Christian Gisselbrecht, Hanneke C. Kluin-Nelemans, Achiel Van Hoof, Michael Unterhalt, Wolfgang Hiddemann, Martin H. Dreyling

Blood (2009) 114 (22): 880.

https://doi.org/10.1182/blood.V114.22.880.880

Published: 2009

Journal Articles

Rituximab Overcomes Sex as a Strong Adverse Prognostic Factor for Treatment Outcome in Patients with Follicular Lymphoma: Analysis of Patients Treated with Rituximab/CHOP or CHOP in Randomized Trials of the German Low Grade Lymphoma Study Group (GLSG).

Christian Buske, MD, Eva Hoster, Martin H. Dreyling, Roswitha Forstpointner, Michael Kneba, MD, PhD, Norbert Schmitz, MD, Rudolf Schmits, Bernd Metzner, Michael Hallek, MD, Eva Lengfelder, Wolfgang Hiddemann, Michael Unterhalt

Blood (2009) 114 (22): 3706.

https://doi.org/10.1182/blood.V114.22.3706.3706

Published: 2009

Journal Articles

Rituximab in Combination with CHOP in Patients with Follicular Lymphoma: Analysis of Treatment Outcome of 552 Patients Treated in a Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG) after a Follow up of 58 Months

Blood (2008) 112 (11): 2599.

https://doi.org/10.1182/blood.V112.11.2599.2599

Published: 2008

Journal Articles

Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG)

Roswitha Forstpointner, Michael Unterhalt, Martin Dreyling, Hans-Peter Böck, Roland Repp, Hannes Wandt, Christiane Pott, John F. Seymour, Bernd Metzner, Annette Hänel, Tanja Lehmann, Frank Hartmann, Hermann Einsele, Wolfgang Hiddemann

Blood (2006) 108 (13): 4003–4008.

https://doi.org/10.1182/blood-2006-04-016725

Published: 2006

Includes: Supplemental data

Journal Articles

Combined Immuno-Chemotherapy Followed by Rituximab Maintenance Is an Effective Salvage Treatment after Prior Rituximab Containing Therapy: Results of a GLSG-Subgroup Analysis in Patients with Relapsed Indolent Lymphoma.

Martin H. Dreyling, MD, Roswitha Forstpointner, MD, Hans-Peter Boeck, MD, Roland Repp, MD, Hannes Wandt, MD, Christiane Pott, MD, John Francis Seymour, MD, Bernd Metzner, MD, Annette Haenel, MD, Tanja Lehmann, MD, Frank Hartmann, MD, Hermann Einsele, MD, Michael Unterhalt, MD, Wolfgang Hiddemann, MD

Blood (2006) 108 (11): 2769.

https://doi.org/10.1182/blood.V108.11.2769.2769

Published: 2006

Journal Articles

Rituximab Maintenance Prolongs Response Duration after Salvage Therapy with R-FCM in Patients with Relapsed Follicular Lymphomas and Mantle Cell Lymphomas: Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG).

Wolfgang Hiddemann, PhD, Roswitha Forstpointner, PhD, Martin Dreyling, PhD, Martin Gramatzki, PhD, Hans-Peter Böck, MD, Mathias Hänel, MD, John Seymour, MD, Manfred Planker, MD, Ulrich Dührsen, PhD, Klaus Wilms, PhD, Martin Clemens, PhD, Wolf-Dieter Ludwig, MD, Hannes Wandt, MD, Rita Pasold, MD, Michael Unterhalt, MD

Blood (2005) 106 (11): 920.

https://doi.org/10.1182/blood.V106.11.920.920

Published: 2005

Journal Articles

The Addition of Rituximab to Combination Chemotherapy with CHOP Has a Long Lasting Impact on Subsequent Treatment in Remission in Follicular Lymhoma but Not in Mantle Cell Lymphoma: Results of Two Prospective Randomized Studies of the German Low Grade Lymphoma Study Group (GLSG).

Wolfgang Hiddemann, MD, PhD, Roswitha Forstpointner, MD, Michael Kneba, MD, PhD, Norbert Schmitz, MD, PhD, Rudolf Schmits, MD, PhD, Bernd Metzner, MD, Marcel Reiser, MD, Eva Lengfelder, MD, PhD, Bernhard Woermann, MD, PhD, Hariett Harder, MD, Susanna Hegewisch-Becker, MD, PhD, Wolfgang Berdel, MD, PhD, Georg Hess, MD, Hartmut Eimermacher, MD, Ali Aldaoud, MD, Manfred Planker, MD, Reza Parwaresch, MD, PhD, Martin Dreyling, MD, PhD, Michael Unterhalt, MD

Blood (2004) 104 (11): 161.

https://doi.org/10.1182/blood.V104.11.161.161

Published: 2004

Journal Articles

CHOP Improves Response Rates but Not Overall Survival in Follicular and Mantle Cell Lymphoma (MCL)- Results of a Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG ).

Christina Nickenig, MD, Martin H. Dreyling, MD, PhD, Eva Schiegnitz, MSc, Michael Pfreundschuh, MD, PhD, Lorenz H. Truemper, MD, PhD, Marcel Reiser, MD, Hannes Wandt, MD, PhD, Eva Lengfelder, MD, PhD, Wolf-Dieter Ludwig, MD, PhD, Wolfgang E. Berdel, MD, PhD, Bernd Metzner, MD, Georg Hess, MD, Roswitha Forstpointner, MD, Reza Parwaresch, MD, PhD, Joerg Hasford, MD, PhD, Michael Unterhalt, MD, Wolfgang Hiddemann, MD, PhD

Blood (2004) 104 (11): 611.

https://doi.org/10.1182/blood.V104.11.611.611

Published: 2004

Journal Articles

The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group

Roswitha Forstpointner, Martin Dreyling, Roland Repp, Sandra Hermann, Annette Hänel, Bernd Metzner, Christiane Pott, Frank Hartmann, Frank Rothmann, Robert Rohrberg, Hans-Peter Böck, Hannes Wandt, Michael Unterhalt, Wolfgang Hiddemann

Blood (2004) 104 (10): 3064–3071.

https://doi.org/10.1182/blood-2004-04-1323

Published: 2004

Journal Articles

Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group

Georg Lenz, Martin Dreyling, Eva Schiegnitz, Roswitha Forstpointner, Hannes Wandt, Mathias Freund, Georg Hess, Lorenz Truemper, Volker Diehl, Martin Kropff, Michael Kneba, Norbert Schmitz, Bernd Metzner, Markus Pfirrmann, Michael Unterhalt, Wolfgang Hiddemann

Blood (2004) 104 (9): 2667–2674.

https://doi.org/10.1182/blood-2004-03-0982

Published: 2004

NARROW

Clinicogenetic Risk Models in Patients Randomized to Receive Consolidative Autologous Stem-Cell Transplantation after Frontline R-CHOP for Advanced Follicular Lymphoma: An Analysis from the GLSG2000 Trial

Chemotherapy-Free Combination of Obinutuzumab and Ibrutinib in First LINE Treatment of Follicular Lymphoma. the Alternative Study By the German Low Grade Lymphoma Study Group (GLSG)

Rituximab Maintenance after First-Line Immunochemotherapy in Mantle Cell Lymphoma: Long-Term Follow-up of the Randomized European MCL Elderly Trial

The Addition of Rituximab to CHOP Improves Failure-Free and Overall Survival of Mantle-Cell Lymphoma Patients – a Pooled Trials Analysis of the German Low-Grade Lymphoma Study Group (GLSG)

Radioimmunotherapy In Relapsed/Refractory Mantle Cell Lymphoma Patients: Final Results Of a European MCL Network Phase II Trial

Autologous Stem Cell Transplantation and Addition of Rituximab Independently Prolong Response Duration in Advanced Stage Mantle Cell Lymphoma.

Rituximab Overcomes Sex as a Strong Adverse Prognostic Factor for Treatment Outcome in Patients with Follicular Lymphoma: Analysis of Patients Treated with Rituximab/CHOP or CHOP in Randomized Trials of the German Low Grade Lymphoma Study Group (GLSG).

Rituximab in Combination with CHOP in Patients with Follicular Lymphoma: Analysis of Treatment Outcome of 552 Patients Treated in a Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG) after a Follow up of 58 Months

Combined Immuno-Chemotherapy Followed by Rituximab Maintenance Is an Effective Salvage Treatment after Prior Rituximab Containing Therapy: Results of a GLSG-Subgroup Analysis in Patients with Relapsed Indolent Lymphoma.

Rituximab Maintenance Prolongs Response Duration after Salvage Therapy with R-FCM in Patients with Relapsed Follicular Lymphomas and Mantle Cell Lymphomas: Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG).

The Addition of Rituximab to Combination Chemotherapy with CHOP Has a Long Lasting Impact on Subsequent Treatment in Remission in Follicular Lymhoma but Not in Mantle Cell Lymphoma: Results of Two Prospective Randomized Studies of the German Low Grade Lymphoma Study Group (GLSG).

CHOP Improves Response Rates but Not Overall Survival in Follicular and Mantle Cell Lymphoma (MCL)- Results of a Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG ).

Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only